Open AccessRetracted: Mucormycosis infection in patients with COVID ‐19: A systematic review
Author(s) -
SeyedAlinaghi SeyedAhmad,
Karimi Amirali,
Barzegary Alireza,
Pashaei Zahra,
Afsahi Amir Masoud,
Alilou Sanam,
Janfaza Nazanin,
Shojaei Alireza,
Afroughi Fatemeh,
Mohammadi Parsa,
Soleimani Yasna,
Nazarian Newsha,
Amiri Ava,
Tantuoyir Marcarious M.,
Oliaei Shahram,
Mehraeen Esmaeil,
Dadras Omid
Publication year - 2022
Publication title -
health science reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 7
ISSN - 2398-8835
DOI - 10.1002/hsr2.529
Subject(s) - mucormycosis , medicine , medline , diabetes mellitus , covid-19 , systematic review , intensive care medicine , web of science , disease , surgery , meta analysis , infectious disease (medical specialty) , endocrinology , political science , law
Several reports previously described mucormycosis co‐infection in patients with COVID‐19. As mucormycosis and COVID‐19 co‐infection might adversely affect patients' outcomes, we aimed to systematically review the related evidence and the subsequent outcomes. Methods We conducted a systematic review of relevant articles searching the keywords in the online databases of PubMed, Scopus, Embase, Cochrane, and Web of Science. All the records from the start of the pandemic until June 12th, 2021 underwent title/abstract and then full‐text screening process, and the eligible studies were included. We did not include any language or time restrictions for the included studies. Results We found 31 eligible studies reporting 144 total cases of COVID‐19 and mucormycosis co‐infection. The nose, cranial sinuses, and orbital cavity were the most commonly involved organs, although the cerebrum, lungs, and heart were also involved in the studies. Pre‐existing diabetes mellitus (DM), as well as corticosteroid use, were the most commonly identified risk factors, but other underlying conditions and immunomodulatory drug use were also present in several cases. Aspergillus was the most commonly reported micro‐organism that caused further co‐infections in patients with concurrent COVID‐19 and mucormycosis. As most of the studies were case reports, no reliable estimate of the mortality rate could be made, but overall, 33.6% of the studied cases died. Conclusion Early diagnosis of mucormycosis co‐infection in COVID‐19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co‐morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co‐infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients.